It is made available under a CC-BY-NC-ND 4.0 International license .

1 <u>Title (100/150):</u> UBTF Tandem Duplications in Pediatric MDS and AML: Implications for

- 2 Clinical Screening and Diagnosis
- 3
- 4 **Short Title (46/50):** UBTF-TDs in Pediatric MDS and AML
- 5

6 Authors and Affiliations:

- Juan M. Barajas^{1,+}, Masayuki Umeda^{1,+}, Lisett Contreras¹, Mahsa Khanlari¹, Tamara
- 8 Westover¹, Michael P. Walsh¹, Emily Xiong¹, Chenchen Yang², Brittney Otero², Marc
- 9 Arribas-Layton², Sherif Abdelhamed¹, Guangchun Song¹, Xiaotu Ma³, Melvin E.
- 10 Thomas 3rd¹, Jing Ma¹, Jeffery M. Klco^{1,*}
- 11 + Equal first authors
- 12 * Corresponding author
- 13 1. Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN,
- 14 USA.
- 15 2. Mission Bio, South San Francisco, CA
- 16 3. Department of Computational Biology, St. Jude Children's Research Hospital,
- 17 Memphis, TN, USA.

18 Contact Information/Corresponding authors:

- 19 *Correspondence: jeffery.klco@stjude.org
- 20 Jeffery M. Klco: Mail Stop 342, Room D4047B, St. Jude Children's Research Hospital,
- 21 262 Danny Thomas Place, Memphis, TN 38105-3678, Phone: (901) 595-6807, Fax:
- 22 (901) 595-5947, Email: jeffery.klco@stjude.org

It is made available under a CC-BY-NC-ND 4.0 International license .

23 Word Count (includes Methods/Introduction/Results/Discussion): 3.090/4.500 24 Figures: 5/7 25 26 27 **Key Points:** 28 Largest cohort of pediatric UBTF-TD in myeloid neoplasms reported to date. • Use of single-cell DNA+protein sequencing technology in 3 UBTF-TD samples 29 • 30 reveals a clonal evaluation pattern characterized by sequential acquisition of 31 WT1 and FLT3 mutations and a more stem cell-like protein expression pattern. Pediatric MDS and AML patients with UBTF-TD alterations dysplastic features 32 • 33 with an increase erythroid precursors. 34 Tandem duplications in exon 9 of *UBTF* represent a rare but functionally • 35 equivalent subgroup of UBTF-TD myeloid neoplasms. 36 37 **Impact Statement:** 38 UBTF tandem duplications (TD) are subtype-defining genomic alterations in adult and

39 pediatric myeloid neoplasms. Here, we provide a comprehensive characterization of the

- 40 largest cohort of pediatric UBTF-TD cases to date, including the recognition of
- 41 additional UBTF alterations that mimic the exon 13 duplications in pediatric AML.

It is made available under a CC-BY-NC-ND 4.0 International license .

43 Abstract, (200/200 words):

Recent genomic studies in adult and pediatric acute myeloid leukemia (AML) 44 demonstrated recurrent in-frame tandem duplications (TD) in exon 13 of upstream 45 46 binding transcription factor (*UBTF*). These alterations, which account for $\sim 4.3\%$ of AMLs in childhood and up to 3% in adult AMLs under 60, are subtype-defining and associated 47 with poor outcomes. Here, we provide a comprehensive investigation into the 48 clinicopathological features of UBTF-TD myeloid neoplasms in childhood, including 89 49 50 unique pediatric AML and 6 myelodysplastic syndrome (MDS) cases harboring a tandem duplication in exon 13 of UBTF. We demonstrate that UBTF-TD myeloid tumors 51 52 are associated with dysplastic features, low bone marrow blast infiltration, and low white blood cell count. Furthermore, using bulk and single-cell analyses, we confirm that 53 54 UBTF-TD is an early and clonal event associated with a distinct transcriptional profile. 55 whereas the acquisition of FLT3 or WT1 mutations is associated with more stem cell-56 like programs. Lastly, we report rare duplications within exon 9 of UBTF that phenocopy 57 exon 13 duplications, expanding the spectrum of UBTF alterations in pediatric myeloid tumors. Collectively, we comprehensively characterize pediatric AML and MDS with 58 59 UBTF-TD and highlight key clinical and pathologic features that distinguish this new 60 entity from other molecular subtypes of AML.

61

62 Key Words:

UBTF Tandem Duplications; Pediatric and Adult Acute Myeloid Leukemia; Myeloid
 Neoplasms

65

It is made available under a CC-BY-NC-ND 4.0 International license .

66 **Introduction:**

67 Pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are characterized by unique genetic backgrounds when compared to those in adults (1-3). 68 69 Recurrent tandem duplications (TD) of exon 13 of upstream binding transcription factor 70 (UBTF) were only recently identified as potential initiating events in pediatric AML (4-7), 71 accounting for about 4% of newly diagnosed pediatric AML. PCR-based screening 72 covering exon 13 of UBTF also identified UBTF-TD alterations in large adult AML 73 cohorts (8, 9). These studies significantly contributed to the accumulation of evidence of UBTF-TD alterations in adult AML. However, PCR-based methods potentially 74 75 underestimate partial tandem duplications (PTD) extending outside the regions covered 76 by amplicons or possible alterations not involving exon 13 (9). Also, data on UBTF 77 alterations in pediatric AML is limited to screening of relatively small cohorts (4, 5), and 78 further efforts are needed to accumulate more knowledge about the biology and 79 clinicopathologic features of this disease entity.

80

UBTF encodes the UBTF/UBF protein known to regulate ribosomal RNA (rRNA) 81 82 transcription and nucleolar formation (10, 11). We previously reported that expression of 83 exon 13 UBTF-TD in cord blood CD34+ (cbCD34+) cells is sufficient to induce cellular 84 proliferation, increase clonogenic activity and the establishment of a transcriptional 85 signature that recapitulates that observed in UBTF-TD AML patient samples (4). Our 86 previous analyses also demonstrated that UBTF-TD do not occur with other canonical alterations in pediatric AML, but that UBTF-TD AMLs often harbor additional somatic 87 88 mutations, such as internal tandem duplications in FLT3 (FLT3-ITD) and frameshift

It is made available under a CC-BY-NC-ND 4.0 International license .

mutations in *WT1*. The acquisition of these cooperating mutations can likely contribute to the stepwise progression of the disease and clonal evolution. However, our understanding of how these cooperating mutations contribute to the cellular and disease status remains to be elucidated.

93

94 To bridge these knowledge gaps, we present an extended pediatric cohort of 89 AML 95 and 6 MDS samples with exon 13 UBTF-TD, showing that UBTF-TD is strongly 96 associated with dysplastic features while acquisition of FLT3-ITD is associated with 97 progression from MDS to AML. By leveraging bulk RNA-sequencing and single cell 98 genomics, we show that the co-occurrence of FLT3-ITD and WT1 mutations is 99 associated with stem cell-like phenotypes. Furthermore, we identified tandem duplications within exon 9 of UBTF in two cases transcriptionally resembling exon 13 100 101 UBTF-TD AML. Exon 9 UBTF-TDs contain hydrophobic leucine-rich sequences and can 102 induce leukemic phenotypes in cbCD34+ cells, which recapitulate findings in exon 13 103 UBTF-TD, suggesting that they likely have a shared mechanism and should be 104 classified as the same molecular entity. These findings offer valuable insights to inform 105 future diagnostic strategies and understanding of the molecular basis of UBTF-TD 106 myeloid neoplasms.

107

108 Materials/Subjects and Methods:

109 Cell Culture and Analysis of cord-blood CD34+ Cell Models

110 UBTF-TD cbCD34+ models were generated as previously described (4). Freshly
 111 isolated cord blood CD34+ (cbCD34+) cells were transduced with lentiviral particles

It is made available under a CC-BY-NC-ND 4.0 International license .

from MND-PGK-mCherry constructs expressing N-terminus HA-tagged UBTF-wild-type (WT), N-terminus HA-tagged UBTF-TD, N-Terminus HA-tagged UBTF-TD78-exon9 or N-Terminus HA-tagged UBTF-TD153-exon9. Transduced cells were sorted for mCherry positivity and expanded as previously described(4). Molecular experiments were performed at 40-60 days after sorting unless otherwise noted. For cytospins, 100,000 cells were washed with 1X PBS and spun onto Superfrost Plus Microscope slides (12-660-16, Fisher Scientific) at 800 rpm for 5 min.

119

120 DNA Single-Cell Sequencing and Analysis

121 Single-cell targeted sequencing was performed using Tapestri System from Mission Bio (missionbio.com). A panel of 162 PCR amplicons with an average size of 260bp was 122 123 designed using Tapestri Designer from Mission Bio (designer.missionbio.com), as well 124 as a manually designed amplicon targeting the UBTF exon13 TD region. This panel 125 consists of amplicons targeting UBTF tandem duplicated regions, common mutations in 126 UBTF-TD AML, and mutations specific to cases presented in this manuscript (Supplemental Table 2). Cryopreserved UBTF-TD primary AML samples were thawed 127 and subjected to dead cell removal using the EasySep[™] Dead Cell Removal Kit 128 129 (STEMCELL Technologies, cat# 17899). Live cells were then subjected to the Mission 130 Bio DNA+Protein protocol per manufacturer's instructions (missionbio.com). Libraries 131 were then sequenced on the Novaseg platform (100M read pairs for DNA libraries and 132 225M read pairs for protein libraries). Bam files, loom files, h5 files, and QC metrics were produced via a customization of the Tapestri pipeline developed by Mission Bio 133 134 (support.missionbio.com/hc/en-us). Analysis of the samples was completed using the

It is made available under a CC-BY-NC-ND 4.0 International license .

Mosaic package v3.0.1 (missionbio.github.io/mosaic/). Reads for the *UBTF* and *FLT3*-ITD calls were isolated from bam files using the pysam python package v0.21.0 (github.com/pysam-developers/pysam). Reads were then realigned to ITD contigs reported in previous studies (4) using the BWA aligner v0.7.15-r1140 (12, 13). When necessary, mutation VAFs were adjusted using pysam.

140

141 RNA-sequencing and genomic profiling

142 As we previously performed (1), RNA reads from newly sequenced samples and from 143 publications were mapped to the GRCh37/hg19 human genome assembly using the 144 StrongARM pipeline (14). Chimeric fusion detection was carried out using CICERO 145 (v0.3.0)(15). For somatic mutations calling from RNA-seq BAM files, we applied 146 Bambino (v1.07)(16) for SNV and RNAindel (v3.0.4) (17, 18) focusing on 87 predefined 147 genes recurrently mutated in pediatric AML and myelodysplastic syndrome. UBTF-TD 148 screening was performed as we have reported (4). For the cases with TWIST capture 149 sequencing, we called mutations as previously described (4). We also collected 150 mutation calls with DNA data from referenced publication in Supplemental Table 5.

151

152 Transcriptome analysis

Gene expression analysis was performed as previously described (1). Briefly, an RNAseq cohort was established by integrating UBTF cases with RNA-seq data in this study (n=96) and AML in other categories from the published study (1) (n=837) and cbCD34+ cells (n=5). Reads from aligned RNA-Seq BAM files were assigned to genes and counted using HTSeq (v0.11.2) (19) with the GENCODE human release 19 gene

It is made available under a CC-BY-NC-ND 4.0 International license .

annotation. The count data were transformed to log2-counts per million (log2CPM) 158 159 using Voom available from R package Limma (v3.50.3) (20). The top variable genes 160 were selected using the "vst" method in Seurat package (21). The expression data were 161 then scaled, and PCA (Principal Component Analysis) was performed on the scaled 162 data using the top 265 variable genes. Dimension reduction was performed using 163 UMAP (Uniform Manifold Approximation and Projection) (22) with the top 100 principal components. Differential gene expression analysis was performed by Limma between 164 165 groups as indicated in each figure, and we set Log2 CPM = -1 if it is < -1 based on the Log2 CPM data distribution. P values were adjusted by the Benjamini-Hochberg method 166 167 to calculate the false discovery rate (FDR) using R function p.adjust. Genes with absolute fold change > 2 and FDR < 0.05 were regarded as significantly differentially 168 169 expressed. Gene Set Enrichment Analysis (GSEA) was performed by GSEA (v4.2.3) 170 using MSigDB gene sets c2.all (v7.5.1) (23). Permutations were done 1000 times 171 among gene sets with sizes between 15 and 1500 genes.

172

173 Statistics

174 Details about statistical comparisons are provided in each figure legend. All the

175 computations were done using R or GraphPad Prism, and all *P* values are 2-sided.

176 **Results:**

177 UBTF-TD in pediatric myeloid neoplasms.

Our previous study described the molecular features of 27 pediatric AML cases with tandem duplications in exon 13 of *UBTF* (*UBFT*-TD) (4). To expand the cohort and better understand the biology, we screened RNA-sequencing data of pediatric MDS and

181 AML cases and identified an additional 68 cases from available datasets and previously 182 published studies (2, 24) and routine clinical service at St. Jude Children's Research 183 Hospital. All 95 cases (median age = 14 yrs., range = 2.4-27.4) possessed exon 13 184 UBTF-TDs encoding a consensus hydrophobic leucine-rich ELTRLLARM motif within 185 the duplications (Figure 1A, Supplemental Table 1). The duplications resulted in an 186 increased size of exon 13 (median size = 60 bp, range = 45-339) (Figure 1B). 187 Consistent with previous findings, UBTF-TD did not co-occur with other subtype-188 defining alterations and showed high variant allele frequencies (VAFs, median = 36.3%, Interguartile range (IQR) = 10.2%), further supporting our previous assertion that UBTF-189 190 TD alterations are early clonal events (1, 4) (Figure 1C). We further investigated the 191 mutational background of this UBTF-TD cohort, confirming a strong association with a 192 normal or trisomy 8 karyotype (Figure 1C-E), as well as with internal tandem duplications (ITD) in FLT3 (n=55, 57.9%) and mutations in WT1 (n=39, 41.1%), which 193 194 are highly co-occurring (Figure 1F, P=0.011, Fisher's exact test) with 30.1% (n=29) 195 cases harboring both alterations. In addition, 26.6% (n=25) of cases also had at least 196 one mutation in Ras-MAPK pathway genes: NRAS (n=17,17.9%); PTPN11 (n=5, 5.3%); 197 *RIT1* (n=5, 5.3%); *NF1* (n=4, 4.2%); *CBL* (n=2, 2.1%); and *KRAS* (n=2, 2.1%). Other 198 recurrent mutations in myeloid malignancies were rarely observed, including IDH1/IDH2 199 (n=3, 3.2%), BCOR (n=2, 2.1%), and RUNX1 (n=1, 1.1%). Although our previous 200 studies only evaluated AML samples, we also identified UBTF-TD in 6 cases of MDS 201 with normal karyotype. These include 3 out of 46 primary MDS cases (6.2%) from our 202 previously published cohort (2). Five of the six MDS cases were classified as childhood 203 MDS with increased blasts according to the current WHO classification (25) and lacked

It is made available under a CC-BY-NC-ND 4.0 International license .

known germline predispositions to pediatric MDS or monosomy 7/del7q. No *FLT3*-ITD
mutations were detected in the 6 MDS cases, while *WT1* mutations were present in 3
out of the 6 MDS cases, suggesting clonal evolutionary patterns initiating with *UBTF*-TD
alterations.

208

209 To address clonal evolution in UBTF-TD myeloid neoplasms, we utilized a droplet-210 based single cell multi-omics platform from MissionBio (Figure 2)(26). This platform 211 enables the concurrent detection of UBTF-TD alterations and somatic mutations present 212 by a custom targeted DNA panel and cell classification by using DNA-oligo conjugated 213 antibodies targeting cell surface markers at the single cell level (Supplemental Table 214 2). In a single timepoint AML case, we found a clonal UBTF-TD alteration in the myeloid 215 population and subclonal mutations in NRAS (p.G12D), FLT3 (p.V592D), and WT1 216 (p.359fs), suggesting UBTF-TD as an initiating event (Supplemental Table 3, Figure 217 **2A-B**). A WT1 mutation was broadly present in the myeloid population, while NRAS or 218 FLT3 mutations were subclonal to WT1 in a mutually exclusive manner, representing 219 branched evolution of the UBTF-TD-WT1+ clone. We also found that cells with 220 WT1⁺FLT3⁺ mutations were associated with high stem cell marker expression (CD34, 221 CD117, or CD123) compared with the UBTF-TD-only population, whereas the WT1⁺NRAS⁺ population was characterized by low expression of these markers. In a 222 223 diagnosis and relapse-paired case, we found that the identical UBTF-TD was retained 224 through disease progression along with a *FLT3*-ITD alteration (Figure 2C-D). 225 Interestingly, a minor $WT1^+$ (p.R375fs) subclone at diagnosis was eradicated after chemotherapy, whereas a different $WT1^+$ (p.R353fs) clone became dominant at relapse, 226

showing high expression of CD34, CD117, and CD123. These data collectively confirm that *UBTF*-TD is an early initiating event, while somatic mutations are subclonal to *UBTF*-TD, possibly contributing to disease progress toward subclones with unique expression profiles.

231

232 Clinical features of UBTF-TD pediatric myeloid neoplasms

233 UBTF-TD AML showed a variety of morphologic features associated with cellular 234 differentiation, as evidenced by variable FAB (French-American-British) classifications (Figure 3A, Supplemental Table 4). Although AML with maturation (FAB M2) was the 235 236 most common (19/43, 44.2%), cases with FAB M6 (erythroid) features were also 237 observed, as was also recently described for UBTF-TD AMLs in adults(9). Morphologic 238 assessments also revealed that UBTF-TD cases often displayed pleomorphic blasts 239 (Figure 3B), accompanied by background multilineage dysplasia and increased erythroid precursors. UBTF-TD AMLs showed lower white blood cell count (median = 240 8.4×10^{9} /L, IQR = 41.4 \times 10^{9}/L) and bone marrow blast percentage (mean = 33%, IQR = 241 242 41.4%) when compared to other AMLs, including those with similar transcriptional 243 profiles like AML with NUP98-rearrangements or NPM1 mutations(1, 4) (Figure 3C-D). 244 FLT3-ITD, but not WT1 mutations, were associated with a higher WBC count and bone 245 marrow blasts in UBTF-TD AMLs (Figure 3E). Despite the presence of dysplastic 246 features, cytogenetic studies commonly found either a normal karyotype (58/95, 61.1%) 247 or trisomy 8 (27/95, 28.4%), and myelodysplasia-related chromosomal changes or 248 myelodysplasia-related mutations were overall rare, suggesting that UBTF-TD itself 249 contributes to dysplastic features (Supplemental Table 4). Considering these overall

It is made available under a CC-BY-NC-ND 4.0 International license .

features, the majority of UBTF-TD AMLs (83/89, 93.3%) are best classified as "Acute myeloid leukemia with other defined genetic alterations" in the current WHO classification(25) (**Supplemental Table 4**).

253

254 Transcriptional features of UBTF-TD myeloid neoplasms

255 We and others have previously shown that AML with UBTF-TD is characterized by high 256 HOXA and HOXB cluster gene expression, similar to NPM1-mutated or NUP98::NSD1 257 AML (1, 4, 8). To further define the unique expression profiles of UBTF-TD, we 258 established an RNA-seq cohort consisting of various AML subtypes (1) (n=837), cord blood CD34+ samples from healthy donors (n=5), and UBTF-TD AML and MDS 259 260 samples (n=94: 1 UBTF-TD case did not have RNA-seq data available) (Figure 4A). 261 Consistent with previous data, UBTF-TD cases clustered with NPM1-mutated and 262 NUP98::NSD1 AMLs. However, UBTF-TD displayed a significantly higher expression of 263 a subset of HOXB cluster genes (e.g., HOXB8, HOXB9) compared with NUP98::NSD1 264 AML (Figure 4B). We also observed uniquely high expression of histone genes (e.g., 265 HIST1H4F and HIST1H2B1) compared to NPM1-mutated AML (Figure 4C), suggesting transcriptional mechanisms unique to UBTF-TD AML. Within UBTF-TD samples, those 266 267 with FLT3-ITD and WT1 mutations showed unique distribution on the UMAP cluster 268 (Figure 4D), and each mutation group demonstrated differential gene expression 269 against UBTF-TD samples without either mutation (Figure 4E). Co-occurrence of WT1 270 and FLT3-ITD was associated with stemness-related genes (e.g., CD34 and DNTT, 271 Figure 4E-F), and Gene Set Enrichment Analysis (GSEA) confirmed enrichment of stemness or cell cycle-related gene expression in WT1⁺FLT3-ITD⁺ UBTF-TD samples 272

It is made available under a CC-BY-NC-ND 4.0 International license .

(Figure 4G). These results show the unique expression profile of *UBTF*-TD AML and
 the specific influence of additional cooperating mutations, which can likely influence
 patterns of clonal evolution.

276

277 Exon 9 tandem duplications in UBTF

278 Given the recurrent UBTF exon 13 alterations duplicating specific hydrophobic amino 279 acid sequences, we hypothesized that UBTF alterations outside exon 13 resulting in 280 similar amino acid sequences could be found in cases without defining alterations but with a similar expression signature. By close inspection of the UBTF gene using RNA-281 282 sequencing data, we found two pediatric AML cases without exon 13 UBTF-TD or other 283 driver alterations that instead have in-frame tandem duplications (lengths of 78 and 284 153bp) in exon 9 of UBTF (TD-exon9), encoding short hydrophobic amino acid 285 sequences (Figure 5A-B). These cases express HOXA/B cluster genes comparably to 286 exon 13 UBTF-TD (Supplemental Figure 1), and one had a WT1 mutation (Supplemental Table 5). To test whether these exon 9 duplication events could lead to 287 288 leukemic transformation, we expressed both exon 9 duplications in cbCD34+ cells using 289 lentiviral vectors and assessed their impact on cell proliferation, clonogenic potential, 290 and cellular morphology in comparison with control conditions and exon 13 UBTF-TD 291 (Figure 5C-D). Colony forming unit (CFU) assay revealed that expression of both 292 UBTF-TD-exon9 increased total colony number (Figure 5E). After the second round of 293 replating, cells with UBTF-TD-exon9 showed an immature morphology along with 294 erythroid features, similar to exon 13 UBTF-TD expressing cells (Figure 5F). 295 Furthermore, cells expressing UBTF-TD-exon9 as well as UBTF-TD-exon13 showed a

It is made available under a CC-BY-NC-ND 4.0 International license .

proliferative advantage compared to UBTF-WT and vector controls (Figure 5G).
Collectively, these data highlight a tandem duplication in *UBTF* exon 9 as a defining
alteration functionally equivalent to exon 13 tandem duplications.

299

300 Discussion:

301 In this study, we extended our cohort of pediatric myeloid malignancies with exon 13 302 UBTF-TD, which now includes 95 pediatric cases. Similar to studies in adults (9), pediatric myeloid tumors with UBTF-TD are associated with lower bone marrow blast 303 304 infiltration and lower white blood cell count, suggesting a similar clinical presentation. In 305 this pediatric cohort, we observed that UBTF-TD is associated with an M2 morphology 306 subtype (44.2%) according to FAB classification (27). These morphological features 307 align with findings in adult cases, which showed a high prevalence of FAB M6 and M2 308 cases (9). Furthermore, the presence of dysplastic features and the observation that 309 UBTF-TD occurs in cases of pediatric MDS suggest that MDS and AML could be part of 310 a continuum driven by UBTF-TD. Progression to AML may require the acquisition of 311 cooperating mutations such as FLT3-ITD, supported by the finding that none of the MDS cases in this cohort harbor a FLT3-ITD alteration. 312

313

To evaluate the impact of these cooperating mutations on cellular status, we analyzed RNA-seq data of *UBTF*-TD cases with or without mutations, showing that the cooccurrence of *FLT3*-ITD and *WT1* is strongly associated with stem cell features and represented by CD34 expression or quiescent states. These findings were further supported by single cell studies. Given that *WT1* mutations are often subclonal

It is made available under a CC-BY-NC-ND 4.0 International license .

alterations that expand at relapse and that the co-occurrence of these mutations is associated with particularly dismal outcomes (4), acquiring these stem-like features can contribute to resistance to conventional chemotherapy. Furthermore, a recent study showed that UBTF-TD localizes to HOXA/B genomic regions and that Menin inhibition is sufficient to promote terminal differentiation (28). How these other mutations co-operate with UBTF-TD to maintain stem cell features requires further evaluation.

325

326 Given that exon 13 UBTF-TD has been underappreciated in standard computational pipelines, we investigated other possible UBTF alterations in pediatric AML cases 327 328 without a defined driver event and demonstrated that in-frame tandem duplications in 329 exon 9 of UBTF are possible driver alterations. Although rare within cases with UBTF alterations (2/97 UBTF-TD cases, 2.1%), cases with tandem duplications in exon 9 330 331 show similar transcriptional profiles to exon 13 UBTF-TD AML. We further show that 332 exon 9 alterations can induce leukemic changes, including hematopoietic cell growth 333 and increased clonogenicity in cbCD34+ cells similar to exon 13 alterations. At the amino acid level, exon 9 tandem duplications contain amino acid sequences 334 335 (LKDKFDGLTI) that share hydrophobic α -helix structure with recurrently duplicated 336 sequences in exon 13 tandem duplications (LTRLLARM), suggesting a shared 337 mechanism. Importantly, PCR-based screening can underestimate PTD or these exon 9 338 alterations since they are outside the covered regions(9), and we propose that 339 enhanced sequencing-based strategies are needed to accurately diagnose this entity. 340 The findings presented here will help build on our understanding of UBTF-TD myeloid

It is made available under a CC-BY-NC-ND 4.0 International license .

neoplasms and further support it's recognition as a distinct entity in future classificationsystems.

- 343
- 344

345 Acknowledgements:

346 The work was funded by the American Lebanese and Syrian Associated Charities of St. 347 Jude Children's Research Hospital and funds from the US NIH, including F32 HL154636 348 (JMB), U54 CA243124 and R01 CA276079 (JMK). The content, however, does not 349 necessarily represent the official views of the NIH and is solely the responsibility of the authors. The studies were also funded by the Jane Coffin Childs Fund (JMB). JMK 350 351 holds a Career Award for Medical Scientists from the Burroughs Welcome Fund. 352 Support was also provided by Shared Resources provided through the St. Jude 353 Comprehensive Cancer Center (P30-CA21765), Flow Cytometry and Cell Sorting, 354 Comparative Pathology Core, and Genome Sequencing (Hartwell Center).

355

356 Author Contributions:

Contributions: Conceptualization, J.M.K; Methodology, J.M.B., L.C., E.X.; Software,
Validation, J.M.B., L.C., E.X.; Formal Analysis, J.M.B., M.U., B.O., M.A.L., M.K.;
Investigation, J.M.B., M.U., L.C., M.P.W., M.K., M.E.T., X.M.; Resources, J.M.K.; Data
Curation, T.W., G.S.; Writing – Original Draft, J.M.B., M.U.; Writing – Review & Editing,
all authors were involved in review & editing of the manuscript; Visualization, J.M.B.,
M.U.; Supervision, J.M.K., Project Administration, J.M.B., M.U., T.W., S.A., J.M.K.;
Funding Acquisition, J.M.B., J.M.K.

It is made available under a CC-BY-NC-ND 4.0 International license .

364

365 **<u>Competing Interests</u>**: C.Y., B.O., and M.A. are employed by Mission Bio, Inc. No other 366 authors have conflicts to declare.

367

368 Data Availability Statement:

Samples from patients with MDS or AML from St. Jude Children's Research Hospital 369 370 tissue resource core facility were obtained with written informed consent using a 371 protocol approved by the St. Jude Children's Research Hospital institutional review board (IRB). Studies were conducted in accordance with the International Ethical 372 373 Guidelines for Biomedical Research Involving Human Subjects. The expression data 374 newly generated in this study (RNA-Seq: n=3) and scDNA + protein sequencing (n=3) 375 have been deposited in the European Genome-Phenome Archive (EGA) which is 376 hosted by the European **Bioinformatics** Institute (EBI), under accession EGAS00001005760. The remaining RNA-Seq data are available via EGA, St. Jude 377 378 Cloud or TARGET as defined in Supplemental Table 6. Information about TARGET 379 can be found at http://ocg.cancer.gov/programs/target. Other data generated in this study are available in the Supplemental tables or upon request to the corresponding 380 381 author.

382 **Citations:**

383

Umeda M, Ma J, Westover T, Ni Y, Song G, Maciaszek J, et al. Proposal of a
 new genomic framework for categorization of pediatric acute myeloid leukemia
 associated with prognosis. Res Sq. 2023.

Schwartz JR, Ma J, Lamprecht T, Walsh M, Wang S, Bryant V, et al. The
 genomic landscape of pediatric myelodysplastic syndromes. Nat Commun.
 2017;8(1):1557.

Bolouri H, Farrar JE, Triche T, Jr., Ries RE, Lim EL, Alonzo TA, et al. The
 molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural
 alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103-12.

4. Umeda M, Ma J, Huang BJ, Hagiwara K, Westover T, Abdelhamed S, et al.
Integrated genomic analysis identifies UBTF tandem duplications as a recurrent lesion
in pediatric acute myeloid leukemia. Blood Cancer Discov. 2022.

Kaburagi T, Shiba N, Yamato G, Yoshida K, Tabuchi K, Ohki K, et al. UBTFInternal tandem duplication as a novel poor prognostic factor in pediatric acute myeloid
leukemia. Genes Chromosomes Cancer. 2022.

399 6. Stratmann S, Yones SA, Mayrhofer M, Norgren N, Skaftason A, Sun J, et al.
400 Genomic characterization of relapsed acute myeloid leukemia reveals novel putative
401 therapeutic targets. Blood Adv. 2021;5(3):900-12.

402 7. Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer
403 genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.
404 Nature. 2018;555(7696):371-6.

8. Georgi JA, Stasik S, Eckardt JN, Zukunft S, Hartwig M, Rollig C, et al. UBTF
tandem duplications are rare but recurrent alterations in adult AML and associated with
younger age, myelodysplasia, and inferior outcome. Blood Cancer J. 2023;13(1):88.

408 9. Duployez N, Vasseur L, Kim R, Largeaud L, Passet M, L'Haridon A, et al. UBTF
409 tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia.
410 Leukemia. 2023.

411 10. Sanij E, Hannan RD. The role of UBF in regulating the structure and dynamics of
 412 transcriptionally active rDNA chromatin. Epigenetics. 2009;4(6):374-82.

413 11. Moss T, Mars JC, Tremblay MG, Sabourin-Felix M. The chromatin landscape of
414 the ribosomal RNA genes in mouse and human. Chromosome Res. 2019;27(1-2):31415 40.

416 12. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler
417 transform. Bioinformatics. 2010;26(5):589-95.

418 13. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The
419 Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-9.

420 14. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape
421 of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat
422 Genet. 2014;46(5):444-50.

Tian L, Li Y, Edmonson MN, Zhou X, Newman S, McLeod C, et al. CICERO: a
versatile method for detecting complex and diverse driver fusions using cancer RNA
sequencing data. Genome Biol. 2020;21(1):126.

426 16. Edmonson MN, Zhang J, Yan C, Finney RP, Meerzaman DM, Buetow KH.
427 Bambino: a variant detector and alignment viewer for next-generation sequencing data
428 in the SAM/BAM format. Bioinformatics. 2011;27(6):865-6.

429 17. Hagiwara K, Edmonson MN, Wheeler DA, Zhang J. indelPost: harmonizing
430 ambiguities in simple and complex indel alignments. Bioinformatics. 2022;38(2):549-51.

431 18. Hagiwara K, Ding L, Edmonson MN, Rice SV, Newman S, Easton J, et al.
432 RNAIndel: discovering somatic coding indels from tumor RNA-Seq data. Bioinformatics.
433 2020;36(5):1382-90.

434 19. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-435 throughput sequencing data. Bioinformatics. 2015;31(2):166-9.

436 20. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers
437 differential expression analyses for RNA-sequencing and microarray studies. Nucleic
438 Acids Res. 2015;43(7):e47.

439 21. Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of 440 single-cell gene expression data. Nat Biotechnol. 2015;33(5):495-502.

441 22. Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG, et al.

442 Dimensionality reduction for visualizing single-cell data using UMAP. Nat Biotechnol.443 2018.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et
al. Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50.

447 24. Fornerod M, Ma J, Noort S, Liu Y, Walsh MP, Shi L, et al. Integrative Genomic
448 Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and
449 Prognostic Indicators. Blood Cancer Discov. 2021;2(6):586-99.

450 25. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th
451 edition of the World Health Organization Classification of Haematolymphoid Tumours:
452 Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-19.

453 26. Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, Durruthy-Durruthy R, et
454 al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature.
455 2020;587(7834):477-82.

456 27. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al.
457 Proposed revised criteria for the classification of acute myeloid leukemia. A report of the
458 French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-5.

It is made available under a CC-BY-NC-ND 4.0 International license .

28. Barajas JM, Rasouli M, Umeda M, Hiltenbrand RL, Abdelhamed S, Mohnani R,
et al. Acute myeloid leukemias with UBTF tandem duplications are sensitive to Menin
inhibitors. Blood. 2023.

462

463 Figure Legends:

464 Figure 1. Characterization of Tandem Duplications in Exon 13 of UBTF. A. Genomic representation of duplicated regions (grey) from 95 cases with UBTF exon 13 duplications. A 465 466 common duplicated region is outlined in red with the alignment of the resulting amino acid 467 sequence. B. Size assessment of exon 13 resulting from the duplicated regions and associated insertion/deletions. For partial tandem duplications (n=13) extending beyond exon 13, sizes of 468 469 duplicated exon 13 with insertions or deletions are included. C. Genomic landscape of UBTF-TD 470 cases. For each case, variant allele frequency (VAF), diagnosis, karyotype, and sex are shown. 471 D. Distribution of cytogenetic changes among UBTF-TD cases. E. Ribbon plot depicting 472 association of cytogenetics with mutations common in UBTF-TD myeloid neoplasms. Genes 473 coding for proteins involved in RAS/MAPK pathway are grouped together (NF1, PTPN11, 474 NRAS, KRAS, RIT1, CBL). All other mutations in FLT3 not classified as ITD were grouped into 475 FLT3-other. F. Ribbon plot depicting the association of co-occurring mutations in the UBTF-TD 476 cohort. Genes with only one occurrence were excluded.

477

Figure 2. Clonal Dynamics of UBTF-TD Leukemias. A. Single-cell DNA sequencing coupled with surface marker expression of UBTF-TD case at diagnosis. Heatmap depicting the presence of mutant allele (bottom) and relative protein abundance (top). B. Schematic of clonal structure in UBTF-TD case from A. Percentages are calculated as a proportion of total cells with a somatic mutation. C. Single-cell DNA sequencing of a UBTF-TD case with diagnosis (left) and relapse (right) paired samples. Heatmap depicts the presence of a mutant allele and protein

It is made available under a CC-BY-NC-ND 4.0 International license .

484 expression. **D.** Schematic of clonal dynamics in diagnosis/relapse case from C. Percentages are
485 calculated as a proportion of total cells with a somatic mutation.

486

487 Figure 3. Morphological and Biological Assessment of UBTF-TD. A. Available FAB 488 (French-American-British) classification of UBTF-TD AMLs (n=43). B. Representative Wright-489 Giemsa Staining of bone marrow (BM) aspirates and peripheral blood (PB) smears from 4 490 unique UBTF-TD cases. Case ID, FAB/WHO classification, along with FLT3 and WT1 mutation 491 status, are labeled above. UBTF-TD-3-Childhood MDS with increased blasts: increased 492 erythroid cells with dysplastic morphologic features (top), dysplastic myeloid cells with salmon-493 colored granules, and dysplastic small megakaryocytes (bottom). UBTF-TD-78-AML with other 494 defined genetic alterations (Acute myeloid leukemia with maturation): characteristic blasts 495 and myeloid precursor cells with salmon-colored granules (top) and blasts with small Auer rods 496 (bottom). UBTF-TD-91-AML with other defined genetic alterations (Acute myelomonocytic 497 leukemia): blasts with both myeloid and monocytic/monoblastic morphologic features. PB in this 498 patient is one of the few cases in our cohort showing hyperleukocytosis with many circulating 499 blasts (bottom). UBTF-TD-90-AML with other defined genetic alterations (Acute 500 myelomonocytic leukemia): dysplastic megakaryocytes, increased erythroid cells with 501 dysplastic morphologic features, and blasts, many with monocytic/monoblastic morphologic 502 features. C. White blood cell counts (WBC) for a pediatric AML cohort stratified by oncogenic 503 driver subtypes. **D.** Bone marrow blast percentage for a pediatric AML cohort stratified by 504 oncogenic driver subtypes. E. WBC count and BM blast percentage among UBTF-TD cases 505 with different WT1 and FLT3 mutation status.

506

507 **Figure 4. Transcriptional characterization of UBTF-TD leukemias. A**. UMAP (Uniform 508 Manifold Approximation and Projection) of expression profiles across a cohort of *UBTF*-TD

It is made available under a CC-BY-NC-ND 4.0 International license .

509 (n=94) and pediatric AML (n=839), adapted from a previous study(4). Each dot is colored by 510 subtype-defining alterations. The black box outlines a cluster of cases with HOXA/HOXB 511 dysregulation, which includes all UBTF-TD cases. B. Differentially expressed genes between 512 UBTF-TD AML and NUP98::NSD1 pediatric AML. Representative genes are annotated. C. 513 Differentially expressed genes between UBTF-TD AML and NPM1-mutated pediatric AML. D. 514 Distribution of UBTF-TD cases within the cluster with HOXA/B dysregulation. Each data is 515 colored by the mutational status of UBTF-TD, FLT3-ITD, or WT1. MDS cases are depicted with 516 triangles, and AML cases are with circles. E-top. Schematic depicting the transcriptional 517 comparison of UBTF-TD cases by mutational status. -bottom. Venn diagram showing overlap 518 of differentially expressed genes in FLT3-ITD only cases and FLT3-ITD+/WT1+ cases 519 compared with cases without these mutations. F. Expression CD34 and DNTT with respect to 520 FLT3 and WT1 mutational status. G. GSEA of UBTF-TD cases based on mutational status.

521

522 Figure 5. Exon 9 UBTF Tandem Duplications in Pediatric AML. A. Identification of UBTF-TD cases with tandem duplications in exon 9 of UBTF. UBTF-TD-exon9 on the UMAP plot of the 523 524 Pediatric AML cohort (red circles), adapted from a previous study(4). B. Schematic of UBTF 525 protein, highlighting amino acid sequences encoded in exon 9 of UBTF-WT, UBTF-TD78-exon9, 526 UBTF-TD153-exon9. Duplications resulting in short hydrophobic sequences are labeled in red. 527 Hydrophobic residues are underlined. C. Experimental design to evaluate the transforming 528 potential of UBTF-TD-exon9 mutants D. Immunoblot of lysates from cbCD34+ transduced with 529 UBTF-TD-exon9 vectors and corresponding controls. Antibodies against HA-tag, UBTF, and β-530 actin were used. E. Colony forming unit assay. 2-way ANOVA with two-sided Dunnett's test was 531 applied with UBTF-WT as control F. Cytospins isolated from CFU assay at round 2 of replating 532 (Wright-Giemsa Staining, 400X magnification). G. In vitro growth curves of cbCD34+ cells 533 expressing controls or UBTF-TD-e9 mutants. 2-way ANOVA with Dunnett's test was applied 534 with UBTF-WT as control.

It is made available under a CC-BY-NC-ND 4.0 International license .

535

It is made available under a CC-BY-NC-ND 4.0 International license .

537



Mutation Types MISSENSE FRAMESHIFT NONSENSE ITD PROTEININS SPLICE REGION SPLICE



Figure 2



Figure 3



Figure 4



